- Home
- MNOV vs IMAB Comparison
MNOV vs IMAB Comparison
Compare MNOV & IMAB Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- MNOV
- IMAB
- Stock Information
- Founded
- MNOV 2000
- IMAB 2014
- Country
- MNOV United States
- IMAB United States
- Employees
- MNOV N/A
- IMAB N/A
- Industry
- MNOV Biotechnology: Pharmaceutical Preparations
- IMAB Biotechnology: Pharmaceutical Preparations
- Sector
- MNOV Health Care
- IMAB Health Care
- Exchange
- MNOV Nasdaq
- IMAB Nasdaq
- Market Cap
- MNOV 89.8M
- IMAB 79.9M
- IPO Year
- MNOV 2005
- IMAB 2020
- Fundamental
- Price
- MNOV $1.83
- IMAB $0.97
- Analyst Decision
- MNOV Strong Buy
- IMAB Strong Buy
- Analyst Count
- MNOV 1
- IMAB 3
- Target Price
- MNOV $9.00
- IMAB $8.00
- AVG Volume (30 Days)
- MNOV 21.3K
- IMAB 270.1K
- Earning Date
- MNOV 02-19-2025
- IMAB 03-13-2025
- Dividend Yield
- MNOV N/A
- IMAB N/A
- EPS Growth
- MNOV N/A
- IMAB N/A
- EPS
- MNOV N/A
- IMAB N/A
- Revenue
- MNOV N/A
- IMAB $569,464.00
- Revenue This Year
- MNOV N/A
- IMAB N/A
- Revenue Next Year
- MNOV N/A
- IMAB N/A
- P/E Ratio
- MNOV N/A
- IMAB N/A
- Revenue Growth
- MNOV N/A
- IMAB N/A
- 52 Week Low
- MNOV $1.12
- IMAB $0.84
- 52 Week High
- MNOV $2.55
- IMAB $2.00
- Technical
- Relative Strength Index (RSI)
- MNOV 43.26
- IMAB 46.51
- Support Level
- MNOV $1.75
- IMAB $0.96
- Resistance Level
- MNOV $2.00
- IMAB $1.04
- Average True Range (ATR)
- MNOV 0.08
- IMAB 0.05
- MACD
- MNOV -0.00
- IMAB -0.00
- Stochastic Oscillator
- MNOV 27.59
- IMAB 36.36
About MNOV Medicinova Inc
MediciNova Inc is a biopharmaceutical company. The company acquires and develops small-molecule therapeutics for the treatment of diseases with unmet medical needs with a specific focus on the U.S. market. Its products portfolio includes therapeutics such as MN-001, MN-166, MN-221 etc. The firm's current strategy is to focus its development activities on therapeutics for neurological disorders and fibrotic diseases.
About IMAB I-MAB
I-MAB is a clinical-stage biotech company. Along with its subsidiaries, it is principally engaged in discovering and developing transformational biologics in the fields of immuno-oncology and immuno-inflammation diseases in the People's Republic of China and other countries and regions. Its drug pipeline includes Uliledlimab (TJD5) which is an antibody for solid tumors, Ragistomig (TJ-L14B), and Givastomig (TJ-CD4B).